BioNTech SE (LON:0A3M)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of GBP 16.53 billion. The enterprise value is 4.58 billion.

Market Cap	16.53B
Enterprise Value	4.58B

Important Dates

The last earnings date was Tuesday, March 10, 2026.

Earnings Date	Mar 10, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.54%
Shares Change (QoQ)	+2.02%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	93.39M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.60
PB Ratio	0.99
P/TBV Ratio	1.10
P/FCF Ratio	67.46
P/OCF Ratio	41.56
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.62
EV / Sales	1.80
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	18.69

Financial Position

The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.01.

Current Ratio	7.54
Quick Ratio	6.87
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	0.95
Interest Coverage	-89.20

Financial Efficiency

Return on equity (ROE) is -5.88% and return on invested capital (ROIC) is -25.47%.

Return on Equity (ROE)	-5.88%
Return on Assets (ROA)	-3.56%
Return on Invested Capital (ROIC)	-25.47%
Return on Capital Employed (ROCE)	-6.38%
Weighted Average Cost of Capital (WACC)	12.57%
Revenue Per Employee	320,690
Profits Per Employee	-126,951
Employee Count	7,807
Asset Turnover	0.13
Inventory Turnover	3.10

Taxes

In the past 12 months, BioNTech SE has paid 74.41 million in taxes.

Income Tax	74.41M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.78% in the last 52 weeks. The beta is 1.53, so BioNTech SE's price volatility has been higher than the market average.

Beta (5Y)	1.53
52-Week Price Change	-10.78%
50-Day Moving Average	106.32
200-Day Moving Average	104.69
Relative Strength Index (RSI)	36.26
Average Volume (20 Days)	19,505

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.68

Income Statement

In the last 12 months, BioNTech SE had revenue of GBP 2.50 billion and -991.10 million in losses. Loss per share was -4.10.

Revenue	2.50B
Gross Profit	1.97B
Operating Income	-1.11B
Pretax Income	-916.69M
Net Income	-991.10M
EBITDA	-980.63M
EBIT	-1.11B
Loss Per Share	-4.10

Balance Sheet

The company has 11.99 billion in cash and 233.27 million in debt, with a net cash position of 11.75 billion.

Cash & Cash Equivalents	11.99B
Total Debt	233.27M
Net Cash	11.75B
Net Cash Per Share	n/a
Equity (Book Value)	16.77B
Book Value Per Share	66.73
Working Capital	12.22B

Cash Flow

In the last 12 months, operating cash flow was 397.80 million and capital expenditures -152.75 million, giving a free cash flow of 245.05 million.

Operating Cash Flow	397.80M
Capital Expenditures	-152.75M
Free Cash Flow	245.05M
FCF Per Share	n/a

Margins

Gross margin is 78.70%, with operating and profit margins of -44.14% and -39.59%.

Gross Margin	78.70%
Operating Margin	-44.14%
Pretax Margin	-36.61%
Profit Margin	-39.59%
EBITDA Margin	-39.17%
EBIT Margin	-44.14%
FCF Margin	9.79%

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.54%
Shareholder Yield	-0.54%
Earnings Yield	-6.00%
FCF Yield	1.48%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 6.72 and a Piotroski F-Score of 4.

Altman Z-Score	6.72
Piotroski F-Score	4